Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2020 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Completes MarzAA Pharmacokinetic & Pharmacodynamic Study

SOUTH SAN FRANCISCO, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for hemophilia and...
June 08, 2020 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Oral and Poster Presentations at the World Federation of Hemophilia Virtual Summit 2020

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced oral and poster presentations at the upcoming World Foundation of Hemophilia...
May 11, 2020 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports First Quarter 2020 Operating & Financial Results and Provides a Corporate Update

MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedback DalcA Phase 2b study completed, final data to be presented in the second quarter ...
April 28, 2020 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Receives Patent in the European Union for Its Factor IX Portfolio

SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for hemophilia and...
April 21, 2020 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)

SOUTH SAN FRANCISCO, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for hemophilia and...
April 06, 2020 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Pivotal Phase 3 Study Design for MarzAA in Individuals with Hemophilia A or B with Inhibitors

SOUTH SAN FRANCISCO, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company that is developing novel subcutaneous (SQ) therapies for...
February 24, 2020 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the Cowen Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst...
February 20, 2020 16:05 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update

Presented positive clinical and pre-clinical data from its MarzAA and DalcA hemophilia programs Announced a global license and collaboration agreement with Biogen to develop and commercialize...
February 18, 2020 16:05 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and...
February 13, 2020 09:15 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and...